Elizabeth Harmon Stover, MD, PhDDana-Farber Cancer Institute Genomic analysis of plasma cell-free tumor DNA to evaluate clinical mechanisms of drug resistance in ovarian cancer Many ovarian cancers are able to resist drug treatment and therefore recur after months or years, posing a major challenge for clinicians and researchers. Currently research of resistant tumors is limited […]
Read More
Kaitlin Fogg, PhDUniversity of Wisconsin The Influence of Macrophages on the Expansion of Ovarian Cancer Metastases Ovarian tumors metastasize or spread by cells detaching from the primary tumor and implanting on nearby organs such as the omentum, an apron-like membrane that insulates the abdominal organs. The factors that lead to the metastases of ovarian tumors are […]
Read More
Bo Yu, MDUniversity of Washington2017 Cookie Laughlin Bridge Funding Award The role of fallopian tube microbiome in ovarian carcinogenesis Ovarian cancer is the most lethal gynecological cancer in the United States. The high mortality rate is due to a lack of understanding of the origin and development of this disease, which makes both early detection […]
Read More
Srinivas Sridhar, PhDNortheastern University Targeted PARP Inhibitor Nanotherapy for Ovarian Cancer PARP inhibitor therapy has shown promising results in clinical trials for ovarian cancer, but oral administration of these drugs requires high doses leading to toxic side effects, and very little drug actually reaches the tumors. Dr. Sridhar and colleagues have synthesized nano-scale formulations of […]
Read More
Fiona Yull, D.Phil.Vanderbilt University Bromodomain inhibition in ovarian cancer and the tumor microenvironment Scientists are actively working to find new therapies for ovarian cancer as resistance to current therapies, including PARP inhibitors and cisplatin, poses a major problem in the clinic. One promising approach is to develop strategies that activate the patient’s normal immune system […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Overcoming acquired resistance to antiangiogenic therapy by targeting vascular p130cas Angiogenesis, the process of forming a new network of blood vessels from existing ones, is a central hallmark of cancer. In order for a tumor to grow, it must have the blood flow necessary to feed […]
Read More
Carlos Telleria, PhDMcGill University Health Center Proteotoxic Stress Therapy in Ovarian Cancer The majority of ovarian cancers recur 18-24 months after first responding to chemotherapy. Residual cells hide out in the abdominal cavity and often become unresponsive to current chemotherapy when they grow back. Dr. Telleria researches therapies that would be administered chronically after chemotherapy […]
Read More
Fiona Simpkins, MDUniversity of Pennsylvania School of Medicine Circumventing drug resistance mechanisms in CCNE1 amplified ovarian cancers More than 80% of patients with high-grade serous ovarian cancer (HGSOC) develop resistance to treatment and eventually succumb to their disease. The need to develop new treatments for this form of ovarian cancer is dire. About 65% of […]
Read More
Rosana Risques, PhDUniversity of Washington 2017 Pape Family Pilot Study Award Characterization of TP53 mutations in BRCA carcinogenesis Women with inherited mutations in the BRCA1 and BRCA2 genes have a greatly increased risk of developing high-grade serous ovarian cancer (HGSOC). This type of cancer starts as a lesion in the fallopian tube, and these lesions almost always contain cells […]
Read More
Richard Moore, MDUniversity of Rochester Targeting HE4 for Checkpoint Immunotherapy of Ovarian Cancer HE4 is a protein that is highly overproduced in ovarian cancer cells and secreted into the bloodstream and serves as a biomarker for the presence of ovarian cancer. However, HE4 is also causally linked to tumorigenesis by promoting enhanced growth, blood vessel […]
Read More